<DOC>
	<DOCNO>NCT02262026</DOCNO>
	<brief_summary>Functional neuroimaging alcoholism vulnerability : glutamate , reward , impulsivity , Pavlovian-to-instrumental transfer ( PIT ) , part II Saracatinib</brief_summary>
	<brief_title>The Tolerability Effects AZD0530 Individuals With Without Family History Alcoholism</brief_title>
	<detailed_description>To assess effect oral AZ D0530 various dos neuroimaging parameter associate various form impulsivity mediate glutamate-dopamine interaction , ascertain functional magnetic resonance imaging .</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Saracatinib</mesh_term>
	<criteria>Clear History least 1 parent history alcoholism first second degree relative alcoholism substance abuse 1 . Exclusion criterion include : Current diagnosis DSMIVTR Axis I disorder 2 . Report psychotic disorder 1ยบ relative 3 . Auditory visual impairment interfere test take 4 . History prenatal exposure alcohol plus currently meet criterion feature fetal alcohol syndrome 5 . Not speak English fluently nonnative English speaker , educate primary language English &gt; grade 1 6 . Mental retardation ( Full Scale IQ &lt; 70 ) use 2 WASI subtests IQ estimate 7 . Traumatic brain injury loss consciousness &gt; 30 minute , concussion last 30 day 8 . Presence history medical/neurologic illness may affect brain physiology ( e.g. , epilepsy , Multiple Sclerosis ) , include focal brain lesion see structural MRI ( structural scan read licensed radiologist ) 9 . Current pregnancy ( female test urine screen day MRI prior phase drug treatment ) 10 . Positive urine screen presence marijuana , cocaine , opiates breath screen detect presence alcohol , administer lab visit . 11 . Inability comprehend consent form appropriately 12 . Ferromagnetic metal device , clip fragment body ( orbital xray perform need ) . 13 . Current use ( within 30 day screen ) specific psychoactive medication ( e.g. , typical neuroleptic , narcotic analgesic , antiparkinsonian medication , systemic corticosteroid , medication significant central anticholinergic activity , etc. ) . Current use warfarin . 14 . Current use follow medication ( CYP3A4 substrates whose metabolism may slow AZD0530 ) : carbamazepine , colchicine , cyclosporine , disopyramide , fluticasone , quinidine , vinblastine , vincristine , nifedipine . Patients take sildenafil , tadalafil , vardenafil advise stop taking medication duration trial . Patients take follow drug inhibit CYP3A4 isoenzyme : cimetidine , cyclosporine , danazol , fluconazole , grapefruit juice , HIV protease inhibitor , itraconazole , ketoconazole , macrolides , miconazole , nefazodone , omeprazole , ritonavir , verapamil , aromatase inhibitor , docetaxel 15 . Neutropenia define absolute neutrophils count &lt; 1,500/microliter . 16 . Thrombocytopenia define platelet count &lt; 100x103/microliter . 17 . AST , ALT , total bilirubin &gt; 1.5 time upper normal ; serum creatinine , &gt; 2 time upper normal limit , total bilirubin &gt; 1.5 time ULN ; Serum creatinine &gt; 2.0 time ULN . 18 . History interstitial lung disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>